Leerink Swann Reiterates Outperform Rating for Eli Lilly and Co. (LLY)
Eli Lilly and Co. (NYSE:LLY)‘s stock had its “outperform” rating reaffirmed by equities researchers at Leerink Swann in a research report issued on Saturday. They currently have a $92.00 price target on the stock, down from their prior price target of $102.00. Leerink Swann’s price objective points to a potential upside of 33.10% from the stock’s previous close.
Other equities analysts have also issued reports about the company. BMO Capital Markets reiterated a “buy” rating and issued a $94.00 price objective on shares of Eli Lilly and in a research report on Monday, October 3rd. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $89.00 price objective for the company in a research report on Tuesday, September 27th. Goldman Sachs Group Inc. upgraded Eli Lilly and from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $89.00 to $95.00 in a research report on Tuesday, September 27th. Deutsche Bank AG reiterated a “buy” rating on shares of Eli Lilly and in a research report on Tuesday, September 20th. Finally, Jefferies Group reiterated a “buy” rating and issued a $105.00 price objective on shares of Eli Lilly and in a research report on Wednesday, September 14th. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $108.34.
Eli Lilly and (NYSE:LLY) traded up 1.65% during trading on Friday, hitting $69.12. 8,620,682 shares of the stock were exchanged. The firm’s 50 day moving average price is $76.69 and its 200-day moving average price is $77.92. Eli Lilly and has a 1-year low of $64.18 and a 1-year high of $88.16. The stock has a market cap of $73.11 billion, a price-to-earnings ratio of 30.07 and a beta of 0.28.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, October 25th. The company reported $0.88 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.96 by $0.08. Eli Lilly and had a net margin of 11.73% and a return on equity of 23.71%. The business earned $5.19 billion during the quarter, compared to analyst estimates of $4.23 billion. During the same quarter in the prior year, the firm posted $0.89 earnings per share. Eli Lilly and’s revenue for the quarter was up 4.7% compared to the same quarter last year. On average, analysts anticipate that Eli Lilly and will post $3.55 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 9th. Shareholders of record on Tuesday, November 15th will be given a dividend of $0.51 per share. This represents a $2.04 annualized dividend and a yield of 2.95%. The ex-dividend date of this dividend is Thursday, November 10th. Eli Lilly and’s payout ratio is 88.70%.
ILLEGAL ACTIVITY WARNING: “Leerink Swann Reiterates Outperform Rating for Eli Lilly and Co. (LLY)” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally stolen and republished in violation of US and international copyright & trademark law. The correct version of this report can be read at https://www.thecerbatgem.com/2016/11/27/leerink-swann-reiterates-outperform-rating-for-eli-lilly-and-co-lly.html.
In other Eli Lilly and news, insider Maria A. Crowe sold 2,248 shares of the stock in a transaction on Wednesday, October 5th. The stock was sold at an average price of $81.37, for a total transaction of $182,919.76. Following the transaction, the insider now owns 94,319 shares in the company, valued at approximately $7,674,737.03. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.20% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Iowa State Bank purchased a new position in Eli Lilly and during the second quarter valued at $104,000. PineBridge Investments L.P. boosted its position in Eli Lilly and by 208.6% in the second quarter. PineBridge Investments L.P. now owns 1,361 shares of the company’s stock valued at $108,000 after buying an additional 920 shares during the last quarter. Tradewinds Capital Management LLC boosted its position in Eli Lilly and by 22.3% in the third quarter. Tradewinds Capital Management LLC now owns 1,345 shares of the company’s stock valued at $108,000 after buying an additional 245 shares during the last quarter. Integrated Wealth Management boosted its position in Eli Lilly and by 3.7% in the third quarter. Integrated Wealth Management now owns 1,389 shares of the company’s stock valued at $112,000 after buying an additional 50 shares during the last quarter. Finally, Financial Architects Inc raised its stake in Eli Lilly and by 4.5% in the third quarter. Financial Architects Inc now owns 1,423 shares of the company’s stock valued at $114,000 after buying an additional 61 shares during the period. Hedge funds and other institutional investors own 75.11% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Stock Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related stocks with our FREE daily email newsletter.